搜索优化
English
全部
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 天
三期临床数据喜忧参半:PROTAC龙头Arvinas股价暴跌40%背后的技术突围与 ...
Arvinas的三期数据之争,本质是新兴技术从概念到产品的必经试炼。尽管挫折当前,但ESR1突变亚组的成功,标志着PROTAC首次在实体瘤中证实临床价值。对行业而言,这一事件亦传递出明确信号:在“靶点内卷”的创新药红海中,技术突破需与精准医疗深度结合——谁能锁定优势亚群并优化临床设计,谁方能笑到最后。
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
今日热点
Sworn in as Canada's PM
Teixeira pleads guilty
Ordered to reinstate workers
Says he supports ceasefire
200% tariff on EU alcohol?
Strikes deal with DOGE
Smishing scam warning
Texas Tech closes campus
‘Ted Lasso’ is coming back
Man hit by motorcade, dies
CDC nomination withdrawn
Swatting call about gunman
UN report accuses Israel
US influencer sparks outrage
Plane engine catches fire
Trump Tower protest
$3B deal to extend rights
Won't block GOP bill
Out as creative director
Exits bankruptcy protection
March megastorm
To cut 2,000+ jobs
Legendary sportswriter dies
FDA, NIH nominees advance
Top FDA lawyer resigns
Khalil sues Columbia
IRS demotes chief counsel
Police charge stepmother
Hamas to release hostage
To host Golden Globes
反馈